{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"13.2","value":"7.1"},{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"1.2","upperLimit":"NA","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first","dispersionType":"95% Confidence Interval","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The PD-L1 positive population is defined as a visually estimated combined positive score (vCPS) ≥10%; only participants with an objective response (CR or PR) were included in this analysis","reportingStatus":"POSTED","timeFrame":"Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)","title":"Duration of Response (DOR) in the PDL-1 Positive Analysis Set.","type":"SECONDARY","unitOfMeasure":"Months"}